SCOTT MYERS
Profile
Related Companies
Titles
Company Name
Related People
EXECUTIVE OFFICER, DIRECTOR
DIRECTOR
PATRICK BAEUERLE, JOSEPH BAILES, PABLO CAGNONI, MARK CHIN, ALAN COLOWICK, JONATHAN DRACHMAN, JULIE EASTLAND, GEORGIA L. ERBEZ, LUKE EVNIN, DAN HICKLIN, RON HUNT, RONALD HUNT, GERALD MCMAHON, WILLIAM E. PICHT, ANDREW ROBBINS, NATALIE R. SACKS, LAUREN SILVERNAIL, LAUREN P. SILVERNAIL, JOANNE VINEY, LUKE WALKER, LUKE NATHANIEL WALKER, HOLGER WESCHE
DIRECTOR
DAVID ABRAHAM, GORAN ANDO, TIMOTHY BARABE, TIMOTHY C. BARABE, ROBERT L. BRATZLER, CARSTEN BRUNN, WERNER CAUTREELS, DOUGLAS COLE, CARRIE COX, CARRIE S. COX, BRADFORD DAHMS, BRADFORD D. DAHMS, BLAINE DAVIS, NISHAN DE SILVA, COLE DOUGLAS, EMILY ENGLISH, OMID FAROKHZAD, CARL GORDON, CARL L. GORDON, PETER BARTON HUTT, CHRIS JEWELL, LLOYD JOHNSTON, MURAT KALAYOGLU, EDWIN M. KANIA, JR., PETER KELLER, TAKASHI KEI KISHIMOTO, ELONA KOGAN, METIN KURTOGLU, ROBERT LANGER, ROBERT S. LANGER, JR., KEMAL MALIK, MILOS MILJKOVIC, SCOTT D. MYERS, SCOTT DUNSETH MYERS, AMIR NASHAT, AYMERIC SALLIN, AYMERIC S. SALLIN, EARL SANDS, ALISON SCHECTER, LEYSAN SHAYDULLINA, GEORGE SIBER, DAVID SIEWERS, MICHAEL SINGER, STEPHEN SMOLINKSI, STEPHEN SMOLINSKI, TIMOTHY SPRINGER, TIMOTHY A. SPRINGER, YURIY UDALTSOV, PATRICK ZENNER, PATRICK S. ZENNER
EXECUTIVE OFFICER
ANDREW J. ARMANINO, ANDREW J. ARMANINO, JR., EDWARD B. COLLINS, STEPHEN A. CORTESE, KEVIN J. CULLEN, STEPHEN R. DATHE, WAYNE DOIGUCHI, WAYNE S. DOIGUCHI, THOMAS M. DORRANCE, TRAILLE E. EDMOND, RANDALL GREENFIELD, DONALD J. KINTZER, ROCHELLE G. KLEIN, JULIE J. LEVENSON, THOMAS R. MOREHOUSE, VIVIAN MUI, FRANK L. MULLER, THOMAS A. SA, JOHN H. SEARS, STEVEN SHELTON, STEVEN E. SHELTON, MILLICENT C. TRACEY, EDMOND E. TRAILLE, MICHELE WIRFEL
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
$5,000,001 - $25,000,000
Equity
2023-10-25
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
$25,000,001 - $100,000,000
Equity
2023-03-23
D
COMMERCIAL BANKING
STATE COMMERCIAL BANKS [6022]
DECLINE TO DISCLOSE
Debt
2021-08-17
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2020-07-31
D
BIOTECHNOLOGY
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
DECLINE TO DISCLOSE
Equity
2018-11-09

